



ZIOPHARM Oncology, Inc.
 Investor Relations Department
 One First Ave., Parris Building, # 34
 Navy Yard Plaza
 Boston, MA 02199
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: ZIOP

Last Trade:	5.15
Trade Time:	4:00 PM ET Aug 17, 2017
Change:	-0.19 (-3.558%)
Day Range	5.12 - 5.41
52-Week Range	4.84 - 7.88
Volume	1,443,563


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 31, 2017*
[ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities](#)
- Jul 24, 2017*
[ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET](#)
- Jun 28, 2017*
[ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma](#)
- Jun 5, 2017*
[ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting](#)
- Jun 2, 2017*
[ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference](#)

Financials [\[View all \]](#)

- Feb 16, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Jul 31, 2017*
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*
[Quarterly Report \(10-Q\)](#)